The U.S. Food and Drug Administration (FDA) has cleared Soligenix’s (NASDAQ:SNGX) Investigational New Drug (IND) application for Phase 2a clinical trial Evaluating SGX302 in the treatment of patients with Mild-to-Moderate Psoriasis.
This study is designed to evaluate the safety and efficacy of topically-applied SGX302 (synthetic hypericin), will enrol up to 32 patients age 18 years or older with mild to moderate, stable psoriasis covering 2 to 30% of their body.
